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Background. Following mass vaccination campaigns in the African meningitis belt with group Ameningococcal
conjugate vaccine, MenAfriVac (PsA-TT), disease due to group A meningococci has nearly disappeared. Antibody
persistence in healthy African toddlers was investigated.
Methods. African children vaccinated at 12–23 months of age with PsA-TT were followed for evaluation of
antibody persistence up to 5 years after primary vaccination. Antibody persistence was evaluated by measuring
group A serum bactericidal antibody (SBA) with rabbit complement and by a group A–speciﬁc IgG enzyme-linked
immunosorbent assay (ELISA).
Results. Group A antibodies measured by SBA and ELISA were shown to decline in the year following vaccina-
tion and plateaued at levels signiﬁcantly above baseline for up to 5 years following primary vaccination.
Conclusions. A single dose of PsA-TT induces long-term sustained levels of group A meningococcal antibodies
for up to 5 years after vaccination.
Clinical Trials Registration. ISRTCN78147026.
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The “meningitis belt” of sub-Saharan Africa runs across
the continent from Senegal to Ethiopia, and this region
is prone tomajor epidemics ofmeningococcal meningitis,
with a high case fatality rate and serious sequelae. Until
recently, most epidemics were due to group A Neisseria
meningitidis (MenA). The observed reduction in menin-
gococcal meningitis due to MenA has been due to the
development of an affordable group A meningococcal
vaccine, PsA-TT (MenAfriVac, Serum Institute of
India, Ltd). TheMeningitis Vaccine Project, a partnership
between the World Health Organization (WHO) and
PATH, coordinated the development, testing, licensure,
and introduction of this vaccine with the aim of eliminat-
ing epidemic meningitis attributable to MenA [1–4].
Since 2010, PsA-TT has been introduced into coun-
tries across the meningitis belt through mass campaigns
[5, 6]. PsA-TT is expected to confer both longer-lasting
individual protection and herd protection than MenA
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polysaccharide vaccines. Ongoing surveillance shows that no
cases of MenA meningococcal disease have occurred in vacci-
nated individuals [6], but the longevity of this protective im-
mune response is not known. Prior to the introduction of
PsA-TT into the African countries of the meningitis belt, mul-
tiple clinical trials assessed the safety and immunogenicity of
PsA-TT. A trial conducted in children aged 12–23 months
demonstrated that this vaccine was immunogenic and induced
immune memory. However, antibody persistence is key in
maintaining direct and indirect protection [7, 8]. We report
here on the persistence of MenA-speciﬁc antibodies in individ-
uals vaccinated with PsA-TT in early childhood.
METHODS
The study was conducted in accordance with the principles of
the Declaration of Helsinki and in compliance with Good Clin-
ical Practice guidelines. The clinical trial was registered (identi-
ﬁer ISRCTN78147026) at www.controlled-trials.com.
The full details of this study have been reported elsewhere by
Sow et al [9]; in brief, healthy children (aged 12–23 months)
who were fully immunized according to the local Expanded
Programme on Immunization schedule were recruited from 2
urban quarters in Bamako, Mali, and from Basse in the Upper
River region of The Gambia. Subjects received primary vaccina-
tion when aged between 12 and 23 months of either PsA-TT
(10 µg), polysaccharide vaccine (PsACWY), or Haemophilus
inﬂuenzae type b vaccine (Hib-TT) and 10 months later were
revaccinated with 1 of these 3 vaccines (the dose of PsACWY
administered was one-ﬁfth dose). Blood samples were obtained
prior to primary vaccination and revaccination, 4 weeks after pri-
mary vaccination, and 1 and 4 weeks after revaccination, the re-
sults of which were previously reported [9]. Those subjects who
received Hib-TT at the primary and revaccination stages of the ini-
tial trial were vaccinated with PsA-TT at the end of the initial trial
(3–4 years of age at approximately 2 years following enrollment).
The initial trial period followed subjects for 2 years following pri-
mary vaccination. Subjects were later approached for enrollment
into a follow-on study to assess the persistence of group A–speciﬁc
antibodies approximately 5 years after primary vaccination. For
evaluation of antibody persistence, blood samples were obtained
at approximately 1, 2, and 5 years following primary vaccination
(initial trial enrollment) in 3 groups who received (1) a single dose
of PsA-TT at either primary or revaccination stages, (2) two doses
of PsA-TT, and (3) a single dose of PsA-TT at the end of the initial
trial period (at 2 years [104 weeks] after primary vaccination)
(those who received 2 doses of Hib-TT).
Immunogenicity
Blood samples were assayed in the serum bactericidal antibody
(SBA) assay using the group A target strain F8238 (phenotype
A:4,21:P1.20,9, L10) as previously described [10]. The comple-
ment source used in the SBA was pooled serum from 3- to 4-
week-old rabbits (Pel Freez Biologicals). Titers were expressed
as the reciprocal serum dilutions yielding ≥50% killing after
60 minutes.
Group A–speciﬁc immunoglobulin G (IgG) levels were deter-
mined using an enzyme-linked immunosorbent assay (ELISA)
[11], except that the reference serum CDC1992 and monoclo-
nal-pan antihuman IgG Fc labeled with horseradish peroxidase
(Hybridoma Reagent Laboratory) were used. For the reference
serum, CDC1992 was used with the previously assigned group
A–speciﬁc IgG concentration [12]. The lower limit of quantita-
tion for the ELISA was 0.4 µg/mL; concentrations below this
were reported as 0.2 µg/mL.
Statistical Analysis
The SBA geometric mean titers (GMTs) and group A–speciﬁc
IgG geometric mean concentrations (GMCs) between the vaccine
groups at 1 year and 2 years after primary vaccination were com-
pared by mixed-effects modeling adjusted for baseline titers
(concentrations), age, sex, study site, time, and interaction effects
of interest with log2-transformed titers and log10-transformed
concentrations as an outcome. At 5 years after primary vaccina-
tion, the comparisons in SBA GMTs and group A–speciﬁc IgG
GMCs between the vaccine groups of interest were performed by
analysis of covariance adjusted for baseline titers (concentra-
tions), sex, and time. The paired t test was used to compare the
GMTs and GMCs between 2 and 5 years after primary vaccina-
tion. The percentages of subjects with SBA titers ≥128 and group
A–speciﬁc IgG concentrations ≥2 µg/mL along with their exact
binomial 95% conﬁdence intervals (CIs) were provided. All im-
munogenicity analyses were conducted in the intention-to-treat
population. Missing values were treated as missing at random.
All tests were 2-sided with a signiﬁcance level of .05. Data analysis
was performed using SAS software, version 9.1.3.
RESULTS
Study Population
As previously reported [9], 601 Malian and Gambian toddlers
were randomized to receive primary vaccination, of whom
589 completed the revaccination stage. Subjects who were re-
cruited into the PsA-TT and Hib-TT groups and received either
PsA-TT or Hib-TT at the revaccination phase were followed for
antibody persistence at approximately 1, 2, and 5 years after pri-
mary vaccination. Figure 1 shows the subjects’ disposition for
the initial trial period and for the follow-up study period. All
101 subjects from the Mali site were excluded from the 5-year
persistence analysis due to the conﬁrmed and probable receipt
of MenAfriVac as part of the national mass vaccination cam-
paign in 2010–2011 or trivalent meningococcal ACW vaccine
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during an outbreak of group W meningococcal disease. Long-
term persistence was conducted on average 5 years after the
initial trial period with a mean duration of 5.1 years following
primary vaccination.
Serum Bactericidal Antibody Titers
The SBA GMTs and proportion of subjects with SBA titers
≥128 for each study group are shown in Table 1. At 1 year
after primary vaccination, the SBA GMTs of the groups that
had received PsA-TT were signiﬁcantly higher than those that
had not received any MenA-containing vaccine (Hib-TT/Hib-
TT) (P < .0001 for all 3 pairwise comparisons).
The SBA GMTs of those vaccinated with Hib-TT followed by
PsA-TT (Hib-TT/PsA-TT) were higher (P < .0001) than the
GMTs of those who received PsA-TT followed by Hib-TT
(PsA-TT/Hib-TT), with GMTs of 3722.5 (95% CI, 2551.4–
5431.3) and 1035.0 (95% CI, 678.4–1578.9), respectively.
The SBAGMTat 1 year after primary vaccination in thosewho
received 2 doses of PsA-TT (PsA-TT/PsA-TT) was statistically
signiﬁcantly higher than that in those who only received 1 dose
of PsA-TT at primary vaccination (P < .0001) and similar to
those who received 1 dose of PsA-TT at revaccination, with
GMTs of 4485.8 (95% CI, 3579.6–5621.4), 3722.5 (2551.4–
5431.3), and 1035.0 (95% CI, 678.4–1578.9) in the PsA-TT/
PsA-TT, Hib-TT/PsA-TT, and PsA-TT/Hib-TT groups,
respectively.
At 2 years after primary vaccination, the SBA GMT in those
who had not received PsA-TT (Hib-TT/Hib-TT) was signiﬁcan-
tly lower than that of the 3 groups that had received PsA-TT
(P = .0001 for Hib-TT/Hib-TT vs Hib-TT/PsA-TT; P = .0279
for Hib-TT/Hib-TT vs PsA-TT/Hib-TT; and P < .0001 for Hib-
TT/Hib-TT vs PsA-TT/PsA-TT). TheGMTs of the 2 groups that
received a dose of PsA-TT at revaccination were similar at 2
years after primary vaccination, with GMTs of 2720.8 (95%
Figure 1. Subject disposition. Abbreviations: Hib-TT, Haemophilus inﬂuenzae type b–tetanus toxoid vaccine; PsACWY, polysaccharide ACWY vaccine;
PsA-TT, meningococcal A polysaccharide–tetanus toxoid protein conjugate vaccine.
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CI, 1960.1–3776.8) and 2527.6 (95% CI, 1796.9–3555.5) in the
PsA-TT/PsA-TT and Hib-TT/PsA-TT groups, respectively.
However, the GMT of the group that received PsA-TT only
at primary vaccination was lower (1313.7 [95% CI, 875.1–
1971.9]; P = .0225 for PsA-TT/Hib-TT vs Hib-TT/PsA-TT
and P = .0042 for PsA-TT/Hib-TT vs PsA-TT/PsA-TT). At 5
years after primary vaccination, the GMT of those who had not
received PsA-TT in the initial study period but received PsA-TT
at the end of the initial study (Hib-TT/Hib-TT) was statistically
signiﬁcantly higher than that in those vaccinated with only
1 dose of PsA-TT at primary vaccination (P = .0118). At the
same time point, there was no signiﬁcant difference in the
GMTs of the Hib-TT/Hib-TT group and those who received
PsA-TT at revaccination only (Hib-TT/PsA-TT) and those
who received 2 doses of PsA-TT (PsA-TT/PsA-TT). From 2
to 5 years after primary vaccination, the SBA GMTs of the
Hib-TT/Hib-TT group signiﬁcantly increased (P = .004).
At all time points, a high percentage (>95%) of subjects in all
groups that had received PsA-TT had SBA titers ≥128. In those
who had not received PsA-TT (ie, received Hib-TT/Hib-TT), a
lower percentage of subjects had SBA titers ≥128, with 72.1%
(95% CI, 59.2%–82.9%) and 86.9% (95% CI, 75.8%–94.2%) of
subjects achieving this level at 1 year and 2 years after primary
vaccination, respectively; the percentage increased to 100%
(95% CI, 86.8%–100.0%) at 5 years after primary vaccination
(3 years after subjects in the Hib-TT/Hib-TT group received
PsA-TT at the end of the initial study period).
Group A–Speciﬁc IgG
The group A–speciﬁc IgG GMCs (µg/mL) and proportion of
subjects with group A–speciﬁc IgG ≥2 µg/mL of each study
group are shown in Table 2.
At 1 year and 2 years after primary vaccination, the group
A–speciﬁc IgG GMC in all 3 groups that received PsA-TT
was signiﬁcantly higher than that of those who had not received
PsA-TT (Hib-TT/Hib-TT) (P < .0001 for all 3 pairwise compar-
isons at 1 year and 2 years after primary vaccination).
The group A–speciﬁc IgG GMC of the Hib-TT/PsA-TT
group was signiﬁcantly higher than that of the PsA-TT/Hib-
TT group at 1 year after primary vaccination, with GMCs of
1.6 (95% CI, 1.2–2.1) and 0.9 (95% CI, .6–1.3) (P = .0037).
This effect was not found at 2 years after vaccination, though,
with GMCs of 1.2 (95% CI, .9–1.7) and 0.9 (95% CI, .7–1.3) in
the Hib-TT/PsA-TT and PsA-TT/Hib-TT groups, respectively.
At 1 year postvaccination, the group that received 2 doses of
PsA-TT had higher group A–speciﬁc IgG GMCs (7.3 [95%
CI, 5.4–9.8]) than the Hib-TT/PsA-TT group (1.6 [95% CI,
1.2–2.1]) (P < .0001). The GMC of the 2-dose PsA-TT group
was also higher than that of Hib-TT/PsA-TT at 2 years follow-
ing vaccination (P < .0001), with GMCs of 3.7 (95% CI, 2.7–5.0)
and 1.2 (95% CI, .9–1.7), respectively.Ta
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At 5 years after primary vaccination, the GMCs of the PsA-
TT/PsA-TT and Hib-TT/Hib-TT (who had received PsA-TT at
the end of the initial study period) groups were signiﬁcantly
higher than the GMCs in the PsA-TT/Hib-TT and Hib-TT/
PsA-TT groups (P = .0110 for PsA-TT/PsA-TT vs PsA-TT/
Hib-TT; P = .0089 for Hib-TT/Hib-TT vs PsA-TT/Hib-TT;
P = .0483 for PsA-TT/PsA-TT vs Hib-TT/PsA-TT; and
P = .0386 for Hib-TT/Hib-TT vs Hib-TT/PsA-TT), with signif-
icant increases in the PsA-TT/PsA-TT (P = .0149) and Hib-TT/
Hib-TT (P < .0001) groups from 2 years following primary vac-
cination to 5 years following primary vaccination.
DISCUSSION
Children vaccinated with PsA-TT demonstrated sustained SBA
levels from 1 year to 5 years following vaccination that were sig-
niﬁcantly above baseline levels, with the majority of subjects
having SBA titers ≥128.
Direct protection from meningococcal disease and vaccine
effectiveness against susceptibility to disease have been shown
to be associated with high vaccine coverage inducing herd
protection in the population and persistence of circulating an-
tibodies rather than with evidence of immunologic priming (in-
duction of memory with high booster responses) [13]. Earlier
expectations that the ability to prime for immunologic memory
could be a key determinant in direct protection to disease [14,
15] have been revisited in light of the extensive experience with
widespread use of meningococcal C conjugate vaccines and that
of conjugate vaccines against other encapsulated bacteria such
as Hib [15–17]. The ability to generate a booster response on
direct exposure was found not to be sufﬁcient to ensure protec-
tion from disease, as antibody levels in subjects with vaccine
failure showed evidence of an anamnestic immune response
[16, 17]. However, the presence of circulating bactericidal anti-
bodies in adequate quantities, along with interruption of car-
riage, appears to be critical for the protection against invasive
disease caused by Neisseria meningitidis. The assessment of
their persistence over time has now become an essential compo-
nent of the evaluation of new meningococcal vaccines to better
inform decisions on schedules and vaccination programs.
Sow et al [9] reported a decline in antibody levels in the 10
months following PsA-TT vaccination, but the levels reported
were higher than those vaccinated with a PsACWY vaccine. The
results reported here show that there was no further antibody
decline in those vaccinated with 1 dose of PsA-TT when aged
12–23 months, with similar SBA GMTs and IgG GMCs mea-
sured at 1, 2, and 5 years following vaccination, both of which
were signiﬁcantly higher than those measured at baseline.
The group A meningococcal SBA GMTs measured in this
trial at 1 year following 1 dose of PsA-TT were comparable to
those measured in Finnish children vaccinated at a similar ageTa
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with a quadrivalent meningococcal ACWY conjugate vaccine
(ACWY-TT, Nimenrix, GlaxoSmithKline) in which an SBA
GMT of 967 (95% CI, 843–1109.3) at 1 year postvaccination
was observed [18]. However, at the later persistence time points
of 2 and 3 years following vaccination, a decline in GMTs was ob-
served in the trial of Vesikari et al [18], whereas similar GMTs
were measured at 1, 2, and 5 years postvaccination in this trial.
Despite the decline in GMTs, the majority of subjects in the
trial of Vesikari et al had SBA titers ≥128 at all persistence time
points; this was also true of the results reported here. It is of note
that the baseline immunogenicity characteristics of the Finnish
child population [18] were very different to those of our trial re-
ported here and may contribute to the differences observed.
Difference in the SBA GMTs was observed at 1 and 2 years
postvaccination between those who received 1 dose of PsA-TT at
primary vaccination and those who received 2 doses. However,
the same difference was not observed when a single dose of
PsA-TT was administered at an older age of 22–33 months, at
the revaccination visit. Differences between the groups that re-
ceived 1 and 2 doses were also evident with the IgG GMCs, with
those who received 2 doses having higher IgG GMCs at 2 and 5
years after primary vaccination. This is in contrast to the results
observed by Klein et al [19], which showed no difference in the
group A meningococcal SBA GMTs 1 year following vaccina-
tion with 1 dose of quadrivalent meningococcal ACWY vaccine
at 12 months of age or 2 doses at 9 and 12 months of age, with
group A meningococcal SBA GMTs of 259.7 (95% CI, 191.4–
352.3) and 237.2 (95% CI, 187.0–301.0) in those who received
1 or 2 doses, respectively. The SBA GMTs and IgG GMCs of the
Hib-TT/Hib-TT group that received PsA-TT at the end of the
initial trial period at an older age of 3–4 years were similar to
those of the group that received 2 doses of PsA-TT. Despite ob-
served differences in the persisting antibody levels in those who
received 1 or 2 doses of PsA-TT, both the SBA GMTs and IgG
GMCs at 5 years after primary vaccination were signiﬁcantly
above baseline for all groups in which subjects received PsA-
TT during the initial study or at the end of the initial study.
PsA-TT has been introduced into several countries of the
African meningitis belt via mass vaccination campaigns in which
individuals aged 1–29 years received 1 dose. PsA-TT has been
shown to have had a major impact on MenA disease and carriage
in Chad [20]. This study and others [21] have demonstrated the
persistence of antibodies following PsA-TT; however, ongoing ac-
tive surveillance is needed to establish the longer-term duration of
protection provided by PsA-TT. In conclusion, we have demon-
strated that 5 years following a single dose of PsA-TT in African
children aged 12–23 months, the majority are still protected.
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